

Supplementary Table 1: Decline in DLCO% in placebo group over 12 months

	N	Decline in DLCO% predicted, Mean (SD)	P value
Disease duration, years			
0-2	17	17.9 (26.3)	0.03
2-4	29	2.9 (12.7)	
>4	18	8.2 (15.1)	
HRCT Fibrosis score			
0-2	40	8.3 (16.7)	0.22
3-4	25	8.8 (21.6)	
HRCT Ground Glass Opacity score			
0-1	55	8.0 (18.5)	0.32
2-3	10	11.3 (20.0)	
HRCT Honeycombing			
0	38	9.0 (19.7)	0.43
≥1	27	7.8 (17.4)	
Autoantibodies			
SCL-70	17	6.2 (12.7)	0.91
Anti-Polymerase-III/ anti-centromere	5	7.6 (17.7)	
Others	26	9.2 (22.5)	
Overall	66	8.2 (18.6)	

Supplementary Table 2: Linear mixed effects model assessing decline in FVC% predicted

Variable	Regression coefficient	Standard error	P-value
Male sex	-0.005	0.02	0.97
Past Smoker	-.03	0.02	0.15
Baseline dyspnea index	0.008	0.004	0.08
Modified Rodnan skin score	-0.007	0.0009	0.40
Baseline Maximum Fibrosis score	-0.004	0.009	0.66
Month	0.0009	0.002	0.68
Month* HRCT Fibrosis score	-0.003	0.0008	0.001
Disease duration*			
Group A	-.02	0.03	0.55
Group B	-0.001	0.03	0.95
Disease duration* month interaction#			
Month* Group A	-0.0005	0.002	0.82
Month* Group B	-0.0003	0.002	0.87
Autoantibody†			
Anti-SCL 70	-0.02	0.02	0.46
Anti-Polymerase III	-0.04	0.03	0.18

Group C is the reference group; #Month Group C is the reference group; † Anti-centromere/ others is the reference group